---
document_datetime: 2023-09-21 17:06:49
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/velcade-epar-procedural-steps-taken-authorisation_en.pdf
document_name: velcade-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3747836
conversion_datetime: 2025-12-22 11:38:15.248438
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Millennium  Pharmaceuticals,  Ltd  submitted  on  31  January  2003    an  application  for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for  Velcade, through the centralised procedure. After agreement by the CPMP on 21 January 2004, this  medicinal  product  has  been  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No  (EEC) 2309/93 of 22 July 1993 as amended.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur:

Prof Silvio Garattini

Co-Rapporteur:

Dr Markku Toivonen

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 24 February 2003.
- The Rapporteur's first Assessment Report was circulated to all CPMP members on 5 May 2003. The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 28 April 2003.
- During  the  meeting  on  24-26  June  2003,  the  CPMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 26 June 2003.
- The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  28 August 2003
- The GCP inspection relating to the clinical trial protocol M34100-025, requested by CPMP, was carried  out  at  the  following  sites:  Dr  Ann  Traynor, Northwestern University Medical School, Robert  H.  Lurie  Cancer  Center,  676  North  St.  Claire,  Suite  850.  Chicago,  IL  60611,  USA (inspected  8-12  Sep  2003)  and  Dr  James  Berenson,  Cedars-Sinai  Medical  Center,  Beverly Modular 1, 8700 Beverly Blvd., Los Angeles, CA 90048, USA, (inspected 15-19 Sep 2003). The final Integrated Inspection Report was issued on 12 November 2003.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CPMP members on 20 October 2003.
- During the CPMP meeting on 20 November 2003, the CPMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant.
- The applicant submitted the responses to the list of outstanding issues on 12 December 2003.
- During the meeting on 20-21 January 2004, the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation under exceptional circumstances to Velcade on 21 January 2004. The applicant provided the letter of undertaking on the specific obligations and follow-up measures to be fulfilled post-authorisation on 20 January 2004.